Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School, and Senior Physician, Brigham & Women's Hospital in Boston, and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University of Montreal, and Director of Research, Montreal Heart Institute, are Marcelo Di Carli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine, Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former Deputy Division Director, Division of CardioRenal Drug Products, Food and Drug Administration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, and Chief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-Lucien Rouleau, M.D., Dean, Faculty of Medicine, University of Montreal.

"The addition of these well-respected physicians to VIA's clinical advisory board comes at an important time in our history," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "As we prepare for the release of Phase II clinical trial data in the middle of 2008, our clinical advisory board will provide independent medical, scientific, and regulatory guidance in supporting our efforts to advance VIA-2291 as a treatment of cardiovascular disease."

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversib
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... 2014 In contrast to traditional LED ... various colors, Valoya uses proprietary LED technology to incorporate ... possible uniformity which is critical in low proximity installations. ... accuracy throughout its lifetime which is up to four ... , "The investment cost was clearly higher when compared ...
(Date:12/19/2014)... 2014 Egenix, Inc. is pleased to announce that ... the Board, to succeed Donald Fresne ; Mr. Fresne ... as a member of the Board.  In recognition of the ... company over almost twenty years, the Board designated Mr. Fresne ... has established a Search Committee to find a suitable replacement ...
(Date:12/17/2014)... 17, 2014 Based on the ... surgical imaging market is dominated by four major ... imaging market. These players include GE Healthcare (U.K.), ... (Germany). , Full Report Copy at ... Healthcare can be attributed to its strong product ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... 13 Beckman Coulter, Inc. (NYSE: BEC ... that simplify, automate and innovate complex biomedical testing, announced ... October 27, 2010, at 5:00 p.m. ET to discuss ... to the conference call, there will be a webcast ...
... Rice University research that capitalizes on the wide-ranging capabilities ... far more compact and versatile than what is now ... on graphene -- the one-atom-thick form of carbon that ... become key components in future electronic circuits. The discovery ...
... 14, 2010 ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Beckman Coulter to host Conference Call and Webcast Presentation for Third Quarter 2010 Earnings Results on October 27, 2010 2Triple-mode transistors show potential 2550 People Across Europe Will Die Today From a Preventable Lung Disease 2550 People Across Europe Will Die Today From a Preventable Lung Disease 3550 People Across Europe Will Die Today From a Preventable Lung Disease 4550 People Across Europe Will Die Today From a Preventable Lung Disease 5550 People Across Europe Will Die Today From a Preventable Lung Disease 6550 People Across Europe Will Die Today From a Preventable Lung Disease 7550 People Across Europe Will Die Today From a Preventable Lung Disease 8550 People Across Europe Will Die Today From a Preventable Lung Disease 9
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... American Academy of Pediatrics National Children,s Art Contest drew hundreds ... With the theme of "My Healthy Lifestyle," the 2011 ... obesity, diet, exercise, sleep and limiting screen time. This was ... of the three age groups each receive a $500 cash ...
... grown apple may hold within it a tiny bit of ... teamed up on a startup that promises to turn slash ... for farmers that helps their soil hold water and nutrients. ... for farmers. "Wine growers, organic farmers and gardeners of all ...
... generally considered to be a good thing for people ... too risky for women who are also pregnant. Some ... the risk of women developing preeclampsia, a condition that ... this might happen has remained unknown. New research using ...
Cached Biology News:Turning slash piles into soil benefit 2Exercise before and during early pregnancy increases two beneficial proteins for mothers-to-be 2
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
IEX-1 S/L (H-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
Biology Products: